{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Partial Remission at 5 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}],"title":"Stable Disease at 2 Weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Response was assessed by the International Uniform Response Criteria for Multiple myeloma 2016 updated version. Complete Remission (CR) is negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas. Very Good Partial Remission (VGPR) is serum and urine M-protein detectable by immunofixation but not on electrophoresis, or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100mg per 24 h. Partial Remission (PR) is 50% or greater reduction of serum M-protein and 90% or greater reduction in 24-h urinary M-protein (or to less than 200mg per 24 h). Progressive Disease (PD) is serum M-component (minimum absolute increase of 0.5g/dL), or urine M-component (minimum absolute increase of 200mg/24h). Stable Disease (SD) is not meeting criteria for CR, VGPR, PR or progressive disease.","groups":[{"description":"0.66x10\\^6 Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) - Chimeric antigen receptor (CAR) + T cells per kg of recipient bodyweight","id":"OG000","title":"LEVEL 1 - 0.66x10^6 Per Kilogram (kg)"},{"description":"2.0x10\\^6 Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) - Chimeric antigen receptor (CAR) + T cells per kg of recipient bodyweight","id":"OG001","title":"LEVEL 2 - 2.0x10^6 Per kg"},{"description":"6.0x10\\^6 Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) - Chimeric antigen receptor (CAR) + T cells per kg of recipient bodyweight","id":"OG002","title":"LEVEL 3 - 6.0x10^6 Per kg"},{"description":"12.0x10\\^6 Chimeric antigen receptor (CAR) + T cells per kg of recipient bodyweight","id":"OG003","title":"LEVEL 4 - 12.0x10^6 Per kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"3/13 participants enrolled on Level 2 (n=1) and Level 3 (n=2) were not treated. No weeks are necessary for PD.","reportingStatus":"POSTED","timeFrame":"At two and five weeks for stable disease and partial remission, respectively, and up to 5 months and 23 days for progressive disease","title":"Number of Participants With a Response","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}